Maintaining Nonsmoking

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The research is based on a chronic disorder model of cigarette smoking which suggests that long-term treatment targeted to prevent relapse may be useful. Based on this model, the investigators have developed a relapse prevention treatment to intervene on five areas important in relapse prevention, including fluctuating motivation, depression, withdrawal, weight gain, and social support. This treatment protocol has produced high long-term abstinence rates when implemented in a clinical research setting. The current study will evaluate the treatment model when implemented in a medical outpatient setting.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Collaborators: National Institute on Drug Abuse (NIDA); Pfizer
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• At least 18 years of age

• Must be smoking 5 or more cigarettes per day

Exclusion Criteria:

• Previous history of bipolar/manic-depressive disorder

• Current diagnosis of schizophrenia

• Acute life threatening diseases

• Evidence of alcohol or other drug abuse so severe that the patient is judged to be potentially unable to comply with the protocol

• Pregnancy or lactation

• Individuals with out of normal range blood pressure, active angina, valve disease, valve replacement, active cardiomyopathies, myocardial infarction or Coronary artery bypass grafting (CABG) within one year, and Congestive heart failure (CHF)